Full Generic Medicine Info
Dosage/Direction for Use

Cardiac arrhythmias, Angina pectoris, Hypertension
Adult: 25-50 mg every 6-12 hr. Max: 200 mg daily.
CV shock, complicated acute MI; severe conduction disorders, sick sinus syndrome. Severe renal and hepatic insufficiency. Atrial fibrillation/flutter and simultaneous preexcitation syndrome e.g. Wolff-Parkinson-White syndrome.
Special Precautions
1st degree AV block, bradycardia <50 beats/min, hypotension <90 mmHg systolic pressure, heart failure (previous compensation with cardiac glycosides/diuretics required). May impair ability to drive or operate machinery. Pregnancy (especially 1st trimester), lactation.
Adverse Reactions
Rarely, nausea or vertigo, headache, hypotension, dizziness, flushing, bradycardiac arrhythmias, CHF, AV block. Very rarely, allergic skin reactions; reversible increase in transaminases and/or alkaline phosphatase, constipation; ankle oedema; gingival hyperplasia.
Drug Interactions
CV effects enhanced by β-blockers, antiarrhythmics and other drugs with cardiodepressive effects on AV conduction. May intensify BP lowering effect of other antihypertensives. Simultaneous admin of IV β-blockers should be avoided. Digoxin, quinidine, carbamazepine, cimetidine, ranitidine, prazocin, midazolam, lithium, rifampicin, theophylline, phenytoin and phenobarbital may affect the plasma levels of gallopamil, May increase plasma conc of atenolol, metoprolol, propranolol.
Gallopamil is a calcium-channel blocker with antiarrhythmic activity.
CIMS Class
Anti-Anginal Drugs
ATC Classification
C08DA02 - gallopamil ; Belongs to the class of phenylalkylamine derivative selective calcium-channel blockers with direct cardiac effects. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on gallopamil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in